ArticleOncology letters2025
Association between FGF10 expression and gland-forming differentiation pattern in gastric adenocarcinoma: An immunohistochemical analysis.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The histological classification of gastric adenocarcinoma influences its prognostic outcomes and therapeutic strategies. Although fibroblast growth factor (FGF)10 is important for gastric morphogenesis, its use as a molecular marker of gland-forming differentiation pattern remains undefined. The present study examined 117 surgically resected gastric adenocarcinoma specimens using immunohistochemical analysis to evaluate the expression of FGF10 and FGF receptor 2 (FGFR2). Expression patterns in tumor cells and the surrounding stroma were assessed using a four-tier scale. Associations between marker expression and histological differentiation were analyzed by multivariable ordinal logistic regression, adjusting for age, human epidermal growth factor receptor 2 and epidermal growth factor receptor status. Elevated FGF10 expression was significantly associated with well-differentiated, gland-forming histological subtypes, particularly in moderately differentiated tubular adenocarcinoma [adjusted odds ratio (OR) in tumor cells: 1.749, 95% confidence interval (CI) 1.231-2.487, P=0.002; adjusted OR in stroma: 2.418, 95% CI 1.123-5.206, P=0.024]. Conversely, FGFR2 expression showed no association with differentiation pattern (adjusted OR: 0.908, 95% CI 0.452-1.824, P=0.788). Survival analysis revealed no significant relationship between FGF10 or FGFR2 expression level and overall patient survival [hazard ratio (HR) for FGF10 in tumor cells: 0.823, 95% CI 0.640-1.057, P=0.127; HR for FGF10 in stroma: 0.675, 95% CI 0.385-1.183, P=0.170; HR for FGFR2 in tumor cells: 1.080, 95% CI 0.559-2.085, P=0.819]. FGF10 may thus be a promising molecular marker of gland-forming differentiation pattern in gastric adenocarcinoma, offering valuable insights for refining its histopathological classification. These findings may contribute to the development of stratification biomarkers for personalized therapeutic approaches, particularly for the selection of molecular-targeted therapies. The absence of an association with overall survival, however, highlights the need for further investigations into the underlying mechanisms and their broader clinical significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.